LANTHEUS HOLDINGS, INC.
In the published model solve dated 2026-Q2, anchored at $100.77, LANTHEUS HOLDINGS, INC. (LNTH) is priced for +18.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Lantheus is a radiopharmaceuticals company whose engine is PYLARIFY, the leading prostate-cancer PET imaging agent, alongside DEFINITY for echocardiography and a growing neurology imaging line. • The decisive number is PYLARIFY's trajectory: its revenue fell 6.5% year over year to $240.9 million as the prostate-imaging market growth slowed and the agent's transitional reimbursement advantage expired, so the company's single largest product is shrinking [Source: Q1 FY2026 earnings release]. • W
Is LNTH overvalued? See what's priced in →
391 institutional managers reported holding LNTH in 13F filings for the quarter ended 2026-03-31. 60 opened new positions that quarter. Held by BlackRock, Vanguard Group, Farallon Capital, among others. On the short side, 6.1M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (7.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
LNTH has cut its share count 4.1% over the past five years, spending $400.02M on repurchases. It pays no dividend. Cash returned over the past three years: $400.02M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at LNTH over the trailing three years. Absence is a fact about the company, not a signal. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
LNTH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-05 | +14.0% | -12.4% |
| 2023-08-04 | -7.5% | -6.4% |
| 2023-11-03 | -2.7% | +0.3% |
| 2024-05-03 | +12.1% | +4.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
LNTH's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-08-04 (items 1.01, 5.02, 9.01); 2026-08-03 (items 7.01, 8.01, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-05-01 (items 3.03, 5.02, 5.03, 5.07, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.